VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PTGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PTGXProtagonist Therapeutics, Inc.
$124.83$8.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPTGXBalance Sheet

Protagonist Therapeutics, Inc. (PTGX) Balance Sheet

12Y historyFree accessUpdated daily

A debt-to-equity ratio of 0.01 and current ratio of 19.85 in 2026Q3 indicate minimal leverage, although the roughly $500M equity build may partly reflect non-recurring license recognition and an accumulated deficit of -$84.0M persists.

Income StatementBalance SheetCash FlowRatios

PTGX Balance Sheet

Annual statement

PTGX Balance Sheet

Protagonist Therapeutics, Inc. (PTGX) balance sheet — 12-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Total Current Assets1.1B577.57M591.64M355.58M243.08M340.74M315.61M145.31M137.5M150.95M83.24M14.21M9.91M
Cash & Short-Term Investments800.06M567.36M418.91M341.62M237.35M326.9M305.81M133.02M128.85M144M77.6M11.92M9.32M
Cash Only498.3M128.39M97.25M186.73M125.74M123.67M117.36M33.01M82.23M106.03M21.08M4.05M9.32M
Short-Term Investments301.77M438.97M321.66M154.89M111.61M203.24M188.45M100.01M46.62M37.97M56.52M7.87M0
Accounts Receivable286.9M4.5M168.49M10.33M52K5.33M3.82M6.75M4.59M1.82M2.24M715K523K
Days Sales Outstanding59.8635.66141.5662.850.7171.1548.7210.67K54.1433.04---
Inventory000000002.14M-8.75M-7.65M010K
Days Inventory Outstanding-------------
Other Current Assets10.13M0000010K754K-205K10.24M8.16M315K56K
Total Non-Current Assets45.49M92.32M153.08M2.37M4.85M6.96M8.86M9.61M1.97M12.79M10.75M639K415K
Property, Plant & Equipment9.82M11.69M12.61M2.15M4.63M6.73M6.41M7.72M861K879K562K609K415K
Fixed Asset Turnover61.08x3.94x34.46x27.92x5.75x4.06x4.46x0.03x35.92x22.82x---
Goodwill0000000000000
Intangible Assets0000000000000
Long-Term Investments252.91M78.92M140.25M0002M0450K11.46M10.15M30K0
Other Non-Current Assets1.12M0225K225K225K225K450K450K450K450K34K00
Total Assets1.15B669.89M744.73M357.95M247.93M347.69M324.47M154.92M139.47M163.73M93.99M14.85M10.33M
Asset Turnover0.65x0.07x0.58x0.17x0.11x0.08x0.09x0.00x0.22x0.12x---
Asset Growth %70.67%-10.05%108.05%44.38%-28.69%7.16%109.45%11.07%-14.82%74.2%533.14%43.74%-
Total Current Liabilities55.46M45.44M47.4M21.27M31.18M44.02M40.24M35.41M26.16M42.55M6.43M3.13M1.35M
Accounts Payable5.92M5.34M1.61M772K3.64M1.6M3.08M2.79M5.71M1.26M1.16M1.25M349K
Days Payables Outstanding1.4K1.59K--------1.34K1.84K-
Short-Term Debt02.28M510K0000000000
Deferred Revenue (Current)41.8M9.55M18.89M069K2.5M17.21M19M8.22M31.75M000
Other Current Liabilities4.79M15.51M12.62M6.79M4.97M7.13M6.41M4.64M9.5M6.83M120K149K0
Current Ratio19.85x12.71x12.48x16.71x7.80x7.74x7.84x4.10x5.26x3.55x12.94x4.54x7.34x
Quick Ratio19.85x12.71x12.48x16.71x7.80x7.74x7.84x4.10x5.17x3.75x14.13x4.54x7.34x
Cash Conversion Cycle-1.34K------------
Total Non-Current Liabilities6.18M9.74M22.03M01.14M3.66M4.62M39.55M799K547K02.12M1.02M
Long-Term Debt00000009.79M00000
Capital Lease Obligations28.47M8.04M10.36M01.14M3.66M4.5M5.96M00000
Deferred Tax Liabilities1.71M1.71M0221K000000000
Other Non-Current Liabilities0011.68M-221K00121K0799K547K02.12M1.02M
Total Liabilities61.64M55.19M69.43M21.27M32.32M47.67M44.86M74.95M26.96M43.1M6.43M5.25M2.37M
Total Debt8.63M10.32M10.87M1.14M3.66M5.86M5.96M17.01M00000
Net Debt-489.67M-118.07M-86.38M-185.59M-122.09M-117.81M-111.4M-15.99M-82.23M-106.03M-21.08M-4.05M-9.32M
Debt / Equity0.01x0.02x0.02x0.00x0.02x0.02x0.02x0.21x-----
Debt / EBITDA0.03x-0.04x----------
Net Debt / EBITDA-1.47x--0.34x----------
Interest Coverage-------107.89x-459.82x-----
Total Equity1.08B614.71M675.29M336.68M215.61M300.02M279.61M79.96M-140.47M-101.55M-64.59M9.6M7.96M
Equity Growth %80.22%-8.97%100.58%56.15%-28.14%7.3%249.66%156.92%-38.33%-57.22%-773.12%20.63%-
Book Value per Share15.129.6710.385.934.406.488.133.09-6.28-5.74-9.931.631.35
Total Shareholders' Equity1.08B614.71M675.29M336.68M215.61M300.02M279.61M79.96M-140.47M-101.55M-64.59M9.6M7.96M
Common Stock1K1K1K1K000000000
Retained Earnings-84.02M-470.67M-340.52M-615.71M-536.75M-409.36M-283.81M-217.66M-140.47M-101.55M-64.59M-27.42M-12.56M
Treasury Stock-5.79M000000000000
Accumulated OCI-1.29M641K-82K-105K-359K-299K28K-221K-233K-6K-245K-102K-100K
Minority Interest0000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Milestone-dependent cash and revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash Build Driven by Partner Milestones

Based on reported figures, PTGX's cash position rose from $97.2M in 2024Q4 to $498.3M in 2026Q3, a build that appears to rest on episodic partnership receipts rather than recurring operating inflows.

The step-up in total assets from roughly $670M to $1.1B over the last three quarters suggests the balance sheet is strengthening in headline terms. However, the timing of the increase lines up with milestone recognition, which may not repeat on a predictable schedule. Investors should monitor whether cash holds up in quarters without large partner payments.

Liquidity Comfortable but Partner-Dependent

According to the reported balance sheets, PTGX's current ratio of 19.85 in 2026Q3 and cash of $498.3M provide a wide near-term buffer against an operating loss profile that has persisted across the period.

A current ratio this elevated indicates that short-term obligations are minimal relative to liquid assets, which supports near-term solvency. The buffer is nonetheless sensitive to the pace of partner milestone receipts, since quarterly cash swings of more than $300M in recent periods imply that underlying burn is being masked. Investors should treat the liquidity position as adequate but contingent on continued partner execution.

Negligible Leverage Preserves Flexibility

As reported in the balance sheets, PTGX carried $8.6M of total debt against $1.1B of equity in 2026Q3, leaving a debt-to-equity ratio of 0.01 that presents minimal refinancing pressure.

Leverage is effectively immaterial, suggesting the company has funded its programs through equity and collaboration income rather than borrowing. This preserves strategic flexibility and removes debt service as a constraint on cash flow. The more relevant balance sheet pressure is operating burn, not financing obligations.

Accumulated Deficit Persists Despite Profit Quarter

Based on reported figures, PTGX's retained earnings moved from -$470.7M in 2025Q4 to -$84.0M in 2026Q3, a shift driven largely by a single quarter of $220.0M net income rather than sustained profitability.

The improvement in retained earnings narrows but does not eliminate the accumulated deficit, which remains negative across all ten reported quarters. Because the equity gain is concentrated in one period, it likely reflects non-recurring milestone recognition rather than a durable earnings base. Investors should be cautious about extrapolating the equity recovery.

Milestone Accounting Flatters the Headline Balance Sheet

The strongest counterpoint is that PTGX's 2026Q3 equity jump of roughly $500M may reflect non-recurring license recognition, as trailing revenue near $46.0M sits far below the $274.4M reported in that single quarter.

A balance sheet that appears to have strengthened sharply may be distorted by a lumpy revenue event that flows through deferred revenue and retained earnings simultaneously. The reported 89% year-over-year revenue decline and persistent operating losses suggest the underlying cost base has not shrunk. Investors should monitor whether deferred revenue unwinds in future quarters and whether cash declines once milestone inflows stop.

PTGX — Frequently Asked Questions

Quick answers to the most common questions about buying PTGX stock.

What are the total assets of Protagonist Therapeutics, Inc. (PTGX)?

As of 2025, Protagonist Therapeutics, Inc. (PTGX) had total assets of $669.9M including $577.6M in current assets.

How much debt does Protagonist Therapeutics, Inc. (PTGX) have?

Protagonist Therapeutics, Inc. (PTGX) carries total debt of $10.3M, offset by $567.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Protagonist Therapeutics, Inc.?

Protagonist Therapeutics, Inc. (PTGX) has total shareholders' equity (book value) of $614.7M ($9.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Protagonist Therapeutics, Inc.'s current ratio and liquidity?

Protagonist Therapeutics, Inc. (PTGX) reported a current ratio of 12.71x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.